Organigram Holdings stock (CA68620P1018): earnings update keeps cannabis producer in focus

Organigram Holdings recently reported quarterly results and updated investors on its strategy in the competitive cannabis market. Here is what drives the business and where the company sees its main revenue opportunities.

Organigram Holdings, a Canadian cannabis producer listed in both Toronto and on Nasdaq, recently released its results for the second quarter of fiscal 2024 and provided an update on its strategy in the evolving cannabis market, according to a company press release published on 04/09/2024 for the quarter ended 03/31/2024Organigram press release as of 04/09/2024. The update highlighted revenue trends, adjusted EBITDA performance and the company’s focus on branded products, which are relevant for investors following North American cannabis stocks, including those trading on US exchanges.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Organigram Holdings
• Sector/industry: Cannabis, consumer packaged goods
• Headquarters/country: Moncton, Canada
• Core markets: Canadian adult-use cannabis, international medical cannabis
• Key revenue drivers: Branded cannabis flower, pre-rolls, vapes and international bulk sales
• Home exchange/listing venue: Toronto Stock Exchange and Nasdaq (OGI)
• Trading currency: CAD in Toronto, USD on Nasdaq

Organigram Holdings: core business model

Organigram Holdings focuses on producing and marketing cannabis products primarily for the Canadian adult-use market. The company operates cultivation and processing facilities that supply dried flower, pre-rolls, vapes and other formats to provincial distributors across Canada. Its business model combines large-scale cultivation with branded product development aimed at distinct consumer segments, such as value, mainstream and premium offerings, according to corporate information presented on its websiteOrganigram website as of 03/2024.

Beyond domestic sales, Organigram Holdings is also active in international medical and adult-use channels where regulations allow, including exports to markets such as Israel and Australia through supply agreements. These international activities provide diversification away from the highly competitive Canadian recreational market and can create opportunities to leverage its cultivation capacity and quality certifications. The company emphasizes GMP-compliant processes for exports in order to meet regulatory standards in overseas jurisdictions.

The business model includes investment in brands, innovation and manufacturing efficiencies as a way to defend market share in Canada’s crowded cannabis sector. Organigram Holdings has launched and managed several brands positioned in different price tiers and product categories, aiming to capture a broader base of consumers. At the same time, it seeks to optimize production costs and yield in its cultivation facilities, as cost discipline remains a key factor in the cannabis industry where wholesale prices have come under pressure over recent years.

Main revenue and product drivers for Organigram Holdings

According to the company’s second quarter fiscal 2024 report published on 04/09/2024 for the period ended 03/31/2024, Organigram Holdings generated net revenue of 37.6 million CAD, compared with 39.5 million CAD in the same quarter a year earlierOrganigram press release as of 04/09/2024. The company reported that Canadian recreational net revenue remained the largest contributor, while international revenue and wholesale channels also played roles. Management highlighted adjusted EBITDA of 4.0 million CAD for the quarter, returning to positive territory compared with a small loss in the prior-year period.

Within product categories, dried flower and pre-rolls continue to be important revenue drivers for Organigram Holdings, reflecting Canadian consumer preferences. The company has also invested in vapes and other derivative products to address demand for alternative formats. In earlier fiscal 2024 communications, Organigram noted that pre-rolls and infused pre-rolls were among the fastest-growing segments in its portfolio, which helped support market share in key provinces, according to earnings commentary released alongside its resultsOrganigram press release as of 01/15/2024.

International and bulk sales provide another layer of revenue, although these segments can be more volatile due to the timing of large orders and regulatory approvals in importing countries. Organigram Holdings has previously highlighted shipments to overseas partners and the potential for growth in markets that are in earlier stages of cannabis legalization. These sales can help absorb production capacity and improve economies of scale, but they may also involve pricing and compliance complexities that differ from Canadian provincial board channels.

Cost management has been a recurring theme in Organigram’s financial updates. The company has pursued initiatives such as streamlining production processes, optimizing strain selection and managing facility utilization in order to mitigate the impact of industry-wide price compression. According to its fiscal 2023 year-end materials released on 11/28/2023 for the year ended 09/30/2023, Organigram reported improvements in adjusted gross margin compared with earlier periods, reflecting efforts to improve efficiencyOrganigram press release as of 11/28/2023. Maintaining margins remains a key factor for future profitability.

Industry trends and competitive position

The Canadian cannabis industry has seen significant price competition, evolving consumer tastes and regulatory changes since legalization. Organigram Holdings operates in a field of numerous licensed producers that compete on price, product quality and brand recognition. The company has sought to defend its position through differentiated product offerings, investment in brand portfolios and participation in high-growth segments such as infused pre-rolls and vapes. Its management has also emphasized innovation and research into new product formats to remain relevant as consumer preferences shift.

Regulatory developments continue to shape the market environment. In Canada, rules governing THC limits, packaging and marketing can influence product development and brand-building efforts. On the international side, varying regulations around medical cannabis, import permits and domestic cultivation can affect the pace of market entry and growth. Organigram Holdings has indicated that it intends to selectively expand in markets where regulatory frameworks support sustainable business models and where its product and quality standards can offer competitive advantages, according to statements in its fiscal 2024 communicationsOrganigram presentations as of 02/2024.

In the broader context of North American cannabis, US investors often monitor Canadian producers that are listed on US exchanges, as they offer exposure to the sector without directly holding US plant-touching operators that face federal restrictions. Organigram Holdings, through its Nasdaq listing under the ticker OGI, is one of the names accessible to US-based investors through standard brokerage accounts. Its performance is influenced not only by company-specific execution but also by sector sentiment tied to potential regulatory changes in the United States and other key markets.

Why Organigram Holdings matters for US investors

For US investors, Organigram Holdings offers a way to gain exposure to the legal cannabis industry via a company operating under a federal regulatory framework in Canada. The stock trades on Nasdaq under the symbol OGI, which allows participation through typical US trading platforms. Because Organigram’s revenues are currently concentrated in Canada and selected international markets, its business is not directly constrained by US federal cannabis laws, although cross-border regulation still applies. That structure can be relevant for investors who want sector exposure but are attentive to regulatory risk profiles.

Sector developments in the United States, such as potential changes to federal classification of cannabis or banking access, can still influence sentiment and valuations for Canadian-listed producers like Organigram Holdings. When US policy discussions become more favorable, shares of North American cannabis companies often react, even if their operations are not in the United States. Conversely, delays or setbacks in US reform can weigh on sector-wide performance. For investors, these dynamics mean that Organigram’s stock may reflect both its own earnings path and broader expectations about North American cannabis policy.

At the same time, Organigram Holdings remains exposed primarily to the Canadian market’s competitive landscape, which has seen margin pressure and consolidation. US investors looking at the stock may therefore consider how the company balances domestic competition with opportunities in international markets. The ability to grow branded product sales, maintain or improve margins and secure export agreements can influence the company’s long-term trajectory. Its dual listing and disclosures in Canadian and US markets provide regular financial reporting that can be monitored by investors.

Conclusion

Organigram Holdings remains an established participant in the Canadian cannabis sector with shares accessible to US investors via its Nasdaq listing. Recent results for the second quarter of fiscal 2024 showed moderate net revenue with a return to positive adjusted EBITDA, underscoring the company’s focus on cost control and product mix. The business continues to rely on Canadian recreational sales, complemented by international exports and wholesale channels, in a market where competition and pricing pressure are ongoing considerations. Future performance will likely depend on the company’s ability to strengthen branded product positions, expand international opportunities and navigate evolving regulations that shape the broader cannabis landscape in North America and abroad.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.